TheraRadar
← Back
Data updated: Mar 29, 2026

SPRINGWORKS

OncologyGastroenterology
Pharma

SPRINGWORKS is a pharmaceutical company focused on Oncology, Gastroenterology. Key products include OGSIVEO.

2023
Since
2
Drugs
-
Trials
3
Approved (2yr)

Key Drugs

OGSIVEO
nirogacestat hydrobromide
Notch 1 indications · 2023
GOMEKLI
mirdametinib
MEK1 1 indications · 2025

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

GOMEKLI 2025-02-11
Type 1 - New Molecular Entity
GOMEKLI 2025-02-11
Type 3 - New Dosage Form
OGSIVEO 2024-04-04
Manufacturing (CMC)
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 94%
1 drugs Phase 3: 1 Phase 2: 2 Phase 1: 3
Gastroenterology 6%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology
Takeda big-pharma
Oncology, Gastroenterology
Gilead Sciences biotech
Oncology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology